US Treasury expands investment curbs on Chinese AI and biotech firms
The U.S. Treasury announced on 24 October 2026 that it will extend its investment restrictions to cover Chinese companies in artificial intelligence (AI) and biotechnology (biotech). The move, aimed at curbing China’s growing influence in sensitive technologies, will require U.S. investors to seek approval before investing in or acquiring stakes in these firms. The policy is part of a broader U.S. strategy to safeguard national security and maintain a competitive edge in high‑tech sectors.
Market Background
The U.S. has long used export‑control and investment‑restriction tools to limit Chinese access to advanced technologies. In 2024, the U.S. Department of Commerce added several Chinese AI firms to its Entity List, and the Treasury’s Office of Foreign Assets Control (OFAC) tightened sanctions on biotech companies linked to the Chinese government. The latest curbs build on these measures, expanding the scope to include a wider range of AI and biotech entities.
Indian markets have been closely watching these developments. The National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) have seen a surge in tech‑sector trading, with the Nifty 50’s IT index up 12% YTD. However, the tightening U.S. policy could reduce foreign capital flows into Chinese tech, potentially affecting Indian investors who use U.S. funds to gain exposure to the sector. The Reserve Bank of India (RBI) has recently signalled a willingness to review foreign investment rules to ensure compliance with global standards.
Key Developments
| Metric | Value | Signal |
|---|---|---|
| Treasury curbs scope | AI & biotech firms | Bearish |
| Effective date | 1 Jan 2027 | Neutral |
| U.S. investment limit | 5% of total portfolio | Bearish |
| RBI policy review | Pending | Neutral |
The Treasury’s announcement was accompanied by a statement from Secretary Janet Yellen, who said the restrictions are “necessary to protect national security and maintain the United States’ leadership in critical technologies.” The policy will require U.S. investors to obtain a license from the Treasury before investing in or acquiring a stake in a Chinese AI or biotech company. Failure to comply could result in penalties of up to $10 million per violation.
Sector Impact
Technology and Biotech – U.S. investors will face higher compliance costs and reduced access to Chinese AI and biotech firms. This could lead to a shift in capital towards domestic and other foreign tech companies. Indian tech firms such as Tata Consultancy Services (TCS) and Infosys may see a change in funding patterns as global investors reassess risk.
Pharmaceuticals – Chinese biotech companies that supply active pharmaceutical ingredients (APIs) to global markets could see a slowdown in foreign investment, potentially affecting supply chains for Indian pharma firms that rely on these inputs.
Financial Markets – The NSE’s Nifty 50 and BSE’s Sensex may experience increased volatility as investors adjust portfolios. The small‑cap and mid‑cap indices, which have recently recorded a worst weekly decline in two years amid rising oil prices, could see further pressure if global tech funding dries up.
Foreign Direct Investment (FDI) – India’s gross FDI inflows dropped to $11 bn in August 2026, with net inflows down to $3 bn. The tightening U.S. policy could exacerbate this trend, prompting Indian regulators to explore new avenues for attracting foreign capital.
Macro & Regulatory Context
The RBI’s recent policy brief on foreign investment highlighted the need for clearer tax rules and simpler compliance to boost business growth. SEBI has also been reviewing its cross‑border investment guidelines to ensure alignment with global standards. The U.S. curbs may prompt Indian regulators to tighten their own oversight of foreign investment in sensitive sectors.
On the global stage, China has urged the United States to halt the proposed expansion of outbound investment curbs, arguing that it would hamper innovation and economic growth. The Chinese government has also pledged to increase domestic investment in AI and biotech, potentially creating new opportunities for Indian firms.
What to Watch
- U.S. Treasury licensing process – Investors should monitor the rollout of the licensing system, expected to launch in early 2027.
- RBI policy review – Any changes to foreign investment rules could affect Indian investors’ ability to diversify.
- SEBI cross‑border guidelines – Updates may alter the risk profile of Indian tech stocks.
- China’s domestic investment plans – Increased funding in AI and biotech could create new partnership opportunities for Indian firms.
- Quarterly earnings of Indian IT and pharma companies – May reflect shifting capital flows.
Disclaimer: This article is for information only and is not investment advice. Markets involve risk; consult a SEBI‑registered adviser before acting.
